gg2
cefepime
The gist
A new analysis of 22,608 patients linked cefepime to higher odds of death than other β-lactams.
The absolute gap is small, and the FDA's data found no significant increase.
How it unfolded
- 1994Cefepime was approved for medical use.
- 2007A meta-analysis by Yahav et al. found patients treated with cefepime had a 26% higher relative risk of death than those treated with other β-lactam antibiotics.
- Sep 14, 2026Medical Xpress reported a study published in JAMA Network Open re-examining trial data; across more than 100 randomized trials involving 22,608 patients, researchers found a 94.4% probability that cefepime was associated with higher odds of death, with death in 6.6% of cefepime-treated patients versus 6.2% of the comparison group.